trending Market Intelligence /marketintelligence/en/news-insights/trending/a7YnGyukKMiqGescfpjFjQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ligand agrees to reduced royalty rate on sales of medical device

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Ligand agrees to reduced royalty rate on sales of medical device

Ligand Pharmaceuticals agreed to a reduced royalty rate on the sales of CanGaroo in exchange for $10 million.

Aziyo Biologics will make the payment, following which Ligand will receive a 5% royalty on the sales of the medical device, which is intended to securely hold cardiovascular implantable electronic devices such as pacemakers and defibrillators.

Ligand had secured the rights to the device's royalty in May 2016 from CorMatrix Cardiovascular Inc. in exchange for a $17.5 million payment. The agreement provided for a 20% royalty on the sales of the device as well as others.

CorMatrix Cardiovascular has now transferred the commercial rights of CanGaroo to Aziyo Biologics.

Aziyo will pay Ligand up to $10 million in additional, sales-based milestones tied to the commercial success of the currently-marketed products and extend the term on these royalties by one year as part of the royalty rate reduction.